{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:58:21Z","timestamp":1771473501954,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008676","name":"CMC Microsystems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.yebeh.2021.108483","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T22:00:42Z","timestamp":1640210442000},"page":"108483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy"],"prefix":"10.1016","volume":"126","author":[{"given":"Melissa","family":"Maguire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elinor","family":"Ben-Menachem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Patten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leock Y.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108483_b0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0010","unstructured":"European Medicines Agency (EMA). FYCOMPA\u00ae Annex I: Summary of Product Characteristics, January 2021. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fycompa-epar-product-information_en.pdf. Accessed November 8, 2021."},{"key":"10.1016\/j.yebeh.2021.108483_b0015","unstructured":"Food and Drug Administration (FDA). FYCOMPA\u00ae Prescribing Information, February 2021. Available at: https:\/\/www.fycompa.com\/-\/media\/Files\/Fycompa\/Fycompa_Prescribing_Information.pdf. Accessed November 8, 2021."},{"key":"10.1016\/j.yebeh.2021.108483_b0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108483_b0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0030","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108483_b0035","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108483_b0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/JMDH.S160029","article-title":"Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade","year":"2018","journal-title":"J Multidiscip Healthc"},{"key":"10.1016\/j.yebeh.2021.108483_b0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/ane.13197","article-title":"First add-on perampanel for focal-onset seizures: An open-label, prospective study","volume":"141","author":"Kim","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.108483_b0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.18010","article-title":"Clinical experience with perampanel in intractable focal epilepsy over 12 months of follow-up","volume":"8","author":"Kim","year":"2018","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108483_b0055","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/epi.14520","article-title":"Perampanel in routine clinical use across Europe: pooled, multicenter, observational data","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/epi.12492","article-title":"First clinical experiences with perampanel\u2013the Kork experience in 74 patients","volume":"55","author":"Steinhoff","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0065","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study","volume":"59","author":"Villanueva","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3988\/jcn.2018.14.3.296","article-title":"Adverse events during perampanel adjunctive therapy in intractable epilepsy","volume":"14","author":"Youn","year":"2018","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2021.108483_b0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108483_b0080","doi-asserted-by":"crossref","first-page":"106655","DOI":"10.1016\/j.yebeh.2019.106655","article-title":"Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON)","volume":"102","author":"Abril Jaramillo","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108483_b0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7525-1-29","article-title":"The Hospital Anxiety and Depression Scale","volume":"1","author":"Snaith","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.yebeh.2021.108483_b0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.seizure.2016.11.019","article-title":"Using Hospital Anxiety and Depression Scale (HADS) on patients with epilepsy: Confirmatory factor analysis and Rasch models","volume":"45","author":"Lin","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108483_b0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/occmed\/kqu024","article-title":"The hospital anxiety and depression scale","volume":"64","author":"Stern","year":"2014","journal-title":"Occup Med"},{"key":"10.1016\/j.yebeh.2021.108483_b0100","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.yebeh.2021.108483_b0105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/epi.14044","article-title":"Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307","volume":"59","author":"Krauss","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0110","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.108483_b0115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.13279","article-title":"Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial","volume":"57","author":"Meador","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2019.02.009","article-title":"The effect of perampanel on aggression and depression in patients with epilepsy: A short-term prospective study","volume":"67","author":"Goji","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108483_b0125","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1474-4422(15)00229-X","article-title":"Is a separate monotherapy indication warranted for antiepileptic drugs?","volume":"14","author":"Mintzer","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.108483_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2015.10.017","article-title":"Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study","volume":"34","author":"Shah","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108483_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yebeh.2015.05.020","article-title":"Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies","volume":"48","author":"Ko","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108483_b0140","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0145","doi-asserted-by":"crossref","unstructured":"Maguire M. Chapter 12 - The psychopharmacology of epilepsy. In: Reus VI, Lindqvist D, editors. Handbook of clinical neurology: Elsevier; 2019, p. 207-27.","DOI":"10.1016\/B978-0-444-64012-3.00012-5"},{"key":"10.1016\/j.yebeh.2021.108483_b0150","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jpsychires.2013.05.001","article-title":"Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects","volume":"47","author":"Coccaro","year":"2013","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.yebeh.2021.108483_b0155","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioural adverse events in randomized clinical studies of the noncompetetive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0160","doi-asserted-by":"crossref","first-page":"107939","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review","volume":"118","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108483_b0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/epi.12504","article-title":"Adverse effects and safety profile of perampanel: A review of pooled data","volume":"55","author":"Rugg-Gunn","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108483_b0170","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.94.15_supplement.1850","article-title":"Perampanel in patients with a history of psychiatric illness: post hoc analysis of four randomized phase III studies (304, 305, 306, and 335) and their open-label extensions (307 and 335 OLEx)","volume":"94","author":"Kanner","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108483_b0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1535-7597.2005.05106.x","article-title":"Depression in epilepsy: a neurobiologic perspective","volume":"5","author":"Kanner","year":"2005","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2021.108483_b0180","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/1531-8249(200002)47:2<246::AID-ANA17>3.0.CO;2-E","article-title":"Major depression is a risk factor for seizures in older adults","volume":"47","author":"Hesdorffer","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2021.108483_b0185","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0920-1211(90)90010-S","article-title":"An incident case-referent study of epileptic seizures in adults","volume":"6","author":"Forsgren","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108483_b0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ana.20685","article-title":"Depression and suicide attempt as risk factors for incident unprovoked seizures","volume":"59","author":"Hesdorffer","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2021.108483_b0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.yebeh.2003.08.019","article-title":"Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy","volume":"4","author":"Jones","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108483_b0200","unstructured":"US Department of Health and Human Services. Statistical review and evaluation: antiepileptic drugs and suicidality. Available at: https:\/\/www.fda.gov\/files\/drugs\/published\/Statistical-Review-and-Evaluation--Antiepileptic-Drugs-and-Suicidality.pdf. Accessed November 8, 2021."},{"key":"10.1016\/j.yebeh.2021.108483_b0205","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","article-title":"Suicidality risk of newer antiseizure medications: A meta-analysis","volume":"78","author":"Klein","year":"2021","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.yebeh.2021.108483_b0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/epi.16413","article-title":"Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures","volume":"61","author":"Fogarasi","year":"2020","journal-title":"Epilepsia"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:43:16Z","timestamp":1761504196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021007447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":42,"alternative-id":["S1525505021007447"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108483","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108483"}}